GB202217453D0 - Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity - Google Patents

Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity

Info

Publication number
GB202217453D0
GB202217453D0 GBGB2217453.6A GB202217453A GB202217453D0 GB 202217453 D0 GB202217453 D0 GB 202217453D0 GB 202217453 A GB202217453 A GB 202217453A GB 202217453 D0 GB202217453 D0 GB 202217453D0
Authority
GB
United Kingdom
Prior art keywords
autoimmunity
inflammation
diseases
compounds
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB2217453.6A
Other versions
GB2624633A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ontrack Therapeutics Ltd
Original Assignee
Ontrack Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ontrack Therapeutics Ltd filed Critical Ontrack Therapeutics Ltd
Priority to GB2217453.6A priority Critical patent/GB2624633A/en
Publication of GB202217453D0 publication Critical patent/GB202217453D0/en
Priority to PCT/GB2023/053029 priority patent/WO2024110744A1/en
Publication of GB2624633A publication Critical patent/GB2624633A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GB2217453.6A 2022-11-22 2022-11-22 Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity Pending GB2624633A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB2217453.6A GB2624633A (en) 2022-11-22 2022-11-22 Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
PCT/GB2023/053029 WO2024110744A1 (en) 2022-11-22 2023-11-20 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitrile for use in the treatment of diseases and conditions associated with inflammation or autoimmunity

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2217453.6A GB2624633A (en) 2022-11-22 2022-11-22 Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity

Publications (2)

Publication Number Publication Date
GB202217453D0 true GB202217453D0 (en) 2023-01-04
GB2624633A GB2624633A (en) 2024-05-29

Family

ID=84888995

Family Applications (1)

Application Number Title Priority Date Filing Date
GB2217453.6A Pending GB2624633A (en) 2022-11-22 2022-11-22 Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity

Country Status (2)

Country Link
GB (1) GB2624633A (en)
WO (1) WO2024110744A1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4344743A3 (en) * 2018-08-07 2024-06-19 Emory University Heterocyclic flavone derivatives, compositions, and methods related thereto
WO2023227882A1 (en) * 2022-05-24 2023-11-30 Ontrack Therapeutics Limited 4-(6-oxo-2-(trifluoromethyl)-3,6-dihydrochromeno[7,8-d]imidazol-8-yl)benzonitril e for the treatment of diseases and conditions associated with movement disorders
WO2023227881A1 (en) * 2022-05-24 2023-11-30 Ontrack Therapeutics Limited Compounds for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction

Also Published As

Publication number Publication date
GB2624633A (en) 2024-05-29
WO2024110744A1 (en) 2024-05-30

Similar Documents

Publication Publication Date Title
GB202211273D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation
IL289167A (en) 2h-indazole derivatives and their use in the treatment of disease
EP3639833A4 (en) Agent for the prevention or treatment of fat-related diseases and/or inflammation
EP4149482A4 (en) 2'-fucosyllactose for the prevention and treatment of coronavirus-induced inflammation
EP3969125A4 (en) Use of anti-fcrn antibodies in the treatment of pemphighus and pemphigoid diseases
IL280475A (en) A pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
ZA202110225B (en) Plant extract mixture for use in the prevention and/or treatment of chronic inflammatory bowel diseases
PT3937948T (en) Phytoecdysones and the derivatives thereof for use in the treatment of neuromuscular diseases
GB202217453D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
GB202208256D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
GB202208255D0 (en) Compounds for use in the treatment of diseases and conditions associated with inflammation or autoimmunity
IL282718A (en) Compounds for use in the treatment or prophylaxis of pain, inflammation and/or autoimmunity
EP4232066A4 (en) Polypeptides for use in the treatment and prevention of neurodegenerative diseases
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
GB2610895B (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202211274D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with neurodegenerative dysfunction
GB202202541D0 (en) Composition for use in the treatment and/or prevention of mycotoxic disease
GB202304262D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
GB202207559D0 (en) Flavonoid compound for use in the treatment of diseases and conditions associated with movement disorders
IL284298A (en) Compounds for use as therapeutically active substances in the treatment and/or prevention of neuroretinal diseases
GB202217454D0 (en) Compounds for use in the treatment of diseases and conditions associated with anxiety and / or mood disorders
AU2023244447A1 (en) 5-meo-dmt for use in the treatment of sleep disturbance
AU2021381054A9 (en) Pharmaceutical compositions for use in the management and treatment of pain
GB202409801D0 (en) Products for use in the treatment and prevention of allergy and associated lung conditions/diseases
EP4046658A4 (en) Application of non-igf1r-binding substance in prevention and/or treatment of inflammatory diseases